BioPharmSignal logoBioPharmSignal

Biotech News

Alkermes to Report First Quarter Financial Results on May 5, 2026

Alkermes plc (ALKS)Alkermes plcEarnings

DUBLIN --(BUSINESS WIRE)--Apr. 21, 2026-- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST) on Tuesday, May 5, 2026 to discuss the company’s first quarter financial results. The webcast player and accompanying slides may be accessed on

Open original release

Related news

ALKSAlkermes plc2026-05-05 11:00 EST

Alkermes plc Reports First Quarter 2026 Financial Results

ABOSAcumen Pharmaceuticals2026-05-05 20:00 EST

Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026

PRAXPraxis Precision Medicines2026-05-04 20:01 EST

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

HRMYHarmony Biosciences2026-04-23 12:05 EST

Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

XERSXeris Pharmaceuticals2026-04-23 11:30 EST

Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026

AXSMAxsome2026-04-08 11:00 EST

Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4

TSHATaysha Gene Therapies2026-04-29 12:00 EST

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

DNLIDenali Therapeutics2026-07-27 20:01 EST

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

TNXPTonix Pharmaceuticals2026-07-27 11:00 EST

Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026

AXSMAxsome2026-07-14 11:00 EST

Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10

View all latest news

Alkermes plc

Alkermes is a biopharmaceutical company focused on neuroscience, addiction medicine, and specialty therapeutics. Its portfolio combines commercial products and development programs across CNS and related areas.

Recent company news

ALKSAlkermes plc2026-06-04 11:00 EST

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

ALKSAlkermes plc2026-06-03 20:05 EST

Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

ALKSAlkermes plc2026-05-26 11:00 EST

Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

ALKSAlkermes plc2026-05-21 11:00 EST

Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences

ALKSAlkermes plc2026-05-12 11:00 EST

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

Stock data

Close
52.73 USD
Market cap
6.89B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States